
A hormone used to detect heart trouble can also promote dangerous blood clots in experiments, pointing scientists toward a possible way to prevent blockages without disrupting normal healing.
Heart disease remains the leading cause of death in the United States, claiming a life nearly every 34 seconds. For people living with heart failure, a condition in which the heart struggles to pump enough blood throughout the body, doctors often rely on blood tests to detect signs of cardiac stress. Now, researchers have discovered that one of these familiar warning signals may also contribute to a dangerous complication: blood clots that can block circulation and trigger life-threatening events.
The substance is a hormone called B-type natriuretic peptide (BNP). Doctors routinely measure BNP and related protein fragments because elevated levels can indicate heart failure or other cardiovascular problems. Until now, BNP has largely been viewed as a marker of an overworked heart rather than a potential contributor to disease.
Researchers at the Texas A&M University Irma Lerma Rangel College of Pharmacy, part of Texas A&M Health, have found that elevated BNP can directly activate blood platelets and accelerate clot formation. The study, published in Blood, identifies a molecular pathway that could eventually offer a more targeted way to prevent dangerous blood clots.
“We thought that BNP might not only act as a passive marker but actively contributes to the pathogenesis and progression of cardiovascular disease,” said Dr. Zhenyu Li, a professor of pharmaceutical sciences who led the research.
How a heart hormone drives clotting
Platelets normally protect the body from blood loss. When a blood vessel is damaged, these tiny blood components gather at the injury and stick together to help stop bleeding. Problems arise when platelets become overly active and form clots inside blood vessels where they are not needed. Those clots can obstruct circulation, depriving tissues and organs of oxygen, and contribute to emergencies such as heart attacks and pulmonary embolisms, which occur when a clot blocks blood flow in the lungs.
Li’s team traced BNP’s effects to a receptor on the surface of platelets called natriuretic peptide receptor-A (NPRA). Receptors allow cells to respond to specific chemical signals, and the researchers found that BNP activates platelets by binding directly to NPRA.
“It was previously unknown whether platelets even expressed this receptor,” Li explained. “We are the first team to investigate whether BNP directly activates platelets through the NPRA receptor.”
Once BNP attaches to NPRA, it increases the amount of a signaling molecule called cyclic guanosine monophosphate (cGMP) inside platelets. This sets off a chain of cellular responses that makes platelets more likely to stick together and promotes clot growth. In experimental studies involving blood-vessel injury and pulmonary embolism, elevated BNP markedly accelerated clot formation.
The researchers also examined what happened when NPRA was blocked or its gene was removed. Under those conditions, BNP could no longer increase cGMP levels or activate platelets, and the experiments showed protection against abnormal clotting.
“Knocking out the NPRA gene protected against these complications, proving the clotting process is mediated by the NPRA receptor,” Li said.
Higher BNP tracks platelet activity in patients
Blood samples from patients with heart rhythm disorders provided additional evidence. In these patients, higher circulating BNP levels were associated with greater platelet activity. The finding supports a possible connection between BNP and clotting risk in humans, although the association alone does not establish that BNP directly causes blood clots in patients.
People with elevated BNP are already known to face a higher risk of serious cardiovascular events, including heart attacks and pulmonary embolisms. The newly identified pathway offers a possible biological explanation for that relationship. Li emphasized that the discovery emerged from years of work examining platelet activity and cardiovascular disease.
“It has been an ongoing, gradual progression—not a sudden breakthrough, but a logical continuation of our research over the past two decades,” he said.
Preventing clots without dangerous bleeding
The findings could have implications for how dangerous blood clots are prevented. Existing antiplatelet medications reduce the ability of platelets to form clots, but their effects throughout the body can increase the risk of serious internal bleeding. By targeting the interaction between BNP and NPRA, researchers hope to develop treatments that interfere with harmful clot formation while preserving the normal clotting needed to heal injuries.
Such treatments remain experimental. Li suggested that, in the meantime, physicians may need to monitor patients with elevated BNP more closely and consider whether antiplatelet therapy could help reduce their risk of clot-related complications.
Several questions also remain about the mechanism. Although platelets appear central to BNP-driven clotting, the researchers still need to establish how much of the effect comes specifically from NPRA receptors on platelets rather than receptors on other cells. Future studies will selectively remove NPRA from different cell types to clarify their respective roles.
“Platelets appear to be major contributors, and to confirm this further, we need to develop tissue-specific models,” Li said.
The team is now working with Dr. Wenshe Liu, Regents Professor and Harry E. Bovay, Jr. Chair in Chemistry at the Texas A&M College of Arts and Sciences, to identify small molecules capable of blocking the BNP-NPRA interaction. Promising compounds will undergo further testing to determine whether they can prevent BNP-induced platelet activation and thrombosis without broadly disrupting healthy clotting.
“Because patients with high BNP levels face the greatest risk, targeting this pathway opens new opportunities to reduce thrombotic complications while minimizing standard side effects like severe bleeding,” Li said.
Reference: “BNP Promotes Platelet Activation and Thrombosis via its Receptor NPRA: A Paradigm Shift from Biomarker to Effector” by Yan Zhang, Guoying Zhang, Jiaqian Qi, Shahnaz Qadri, Sahebsadat Hajimirzaei, Zhuodong Chai, Yuqi Zhou, Ling Yang, Fatima Z Alshbool, Yihan Wei, Fadi T Khasawneh and Zhenyu Li, 22 September 2026, Blood.
DOI: 10.1182/blood.2026025455
Funding: NIH/National Institutes of Health, American Heart Association
Never miss a breakthrough: Join the SciTechDaily newsletter.
Follow us on Google and Google News.